OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
The ever‐increasing importance of cancer as a leading cause of premature death worldwide	931
Breast cancer early detection: A phased approach to implementation	260
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy	260
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial	195
Mammography screening reduces rates of advanced and fatal breast cancers: Results in 549,091 women	170
Annual report to the nation on the status of cancer, part 1: National cancer statistics	141
Diagnostic, therapeutic, and prognostic implications of the 2021 World Health Organization classification of tumors of the central nervous system	133
The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types	114
Second cancer risk after primary cancer treatment with three‐dimensional conformal, intensity‐modulated, or proton beam radiation therapy	102
Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma	102
Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases	101
Novel HER2–targeted therapies for HER2–positive metastatic breast cancer	98
Ultra‐rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities	97
Pembrolizumab for the treatment of programmed death–ligand 1‒positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE‐028 study	87
A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179	85
Mortality in hospitalized patients with cancer and coronavirus disease 2019: A systematic review and meta‐analysis of cohort studies	85
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study	83
De novo acute myeloid leukemia: A population‐based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017	80
Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospectiv	78
Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax	77
The impact of COVID‐19 on the cancer care of adolescents and young adults and their well‐being: Results from an online survey conducted in the early stages of the pandemic	75
Breast cancer treatment: A phased approach to implementation	74
Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years	72
Outcomes of novel coronavirus disease 2019 (COVID‐19) infection in 107 patients with cancer from Wuhan, China	72
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach	71

Pediatric cancer mortality and survival in the United States, 2001‐2016	69
Impact of the COVID‐19 pandemic on diagnosis of new cancers: A national multicenter study of the Veterans Affairs Healthcare System	68
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials	67
Perioperative COX2 and β‐adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trial	64
Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis	63
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID‐19	60
The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: A systematic analysis for the Global	60
Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017	59
Population‐level impact of coronavirus disease 2019 on breast cancer screening and diagnostic procedures	58
Management of primary skin cancer during a pandemic: Multidisciplinary recommendations	58
Impact of the coronavirus disease 2019 (COVID‐19) pandemic on pediatric oncology care in the Middle East, North Africa, and West Asia region: A report from the Pediatric Oncology East and Mediterranea	57
Low‐dose whole‐lung radiation for COVID‐19 pneumonia: Planned day 7 interim analysis of a registered clinical trial	57
Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial	55
Oral infectious bacteria in dental plaque and saliva as risk factors in patients with esophageal cancer	54
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies	50
The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource‐Stratified Phased Implementation: Methods and overview	49
Emerging cancer incidence trends in Canada: The growing burden of young adult cancers	47
Multivariate mortality analyses in COVID‐19: Comparing patients with cancer and patients without cancer in Louisiana	47
Impact of the COVID‐19 pandemic on a population‐based breast cancer screening program	47
A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort	47
Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women’s Health Initiative	46
Age distributions of breast cancer diagnosis and mortality by race and ethnicity in US women	46
Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial	46
Accelerated aging among childhood, adolescent, and young adult cancer survivors is evidenced by increased expression of p16^INK4a and frailty	46